Oral Immunotherapy in Children: Clinical Considerations and Practical Management

References

• Gupta RS, Warren CM, Smith BM, et al. The public health impact of parent-reported childhood food allergies in the United States. Pediatrics. 2018;142(6):e20181235. doi:10.1542/peds.2018-1235
   PubMed Web of Science ®Google Scholar
• Loh W, Tang MLK. The epidemiology of food allergy in the global context. Int J Environ Res Public Health. 2018;15(9):2043. doi:10.3390/ijerph15092043
   PubMed Web of Science ®Google Scholar
• Lin CH. Food allergy: what it is and what it is not? Curr Opin Gastroenterol. 2019;35(2):114–118. doi:10.1097/MOG.0000000000000506
   Web of Science ®Google Scholar
• Sampath V, Sindher SB, Pinzon AMA, Nadeau KC. Can food allergy be cured? What are the future prospects? Allergy. 2020;75(6):1316–1326. doi:10.1111/all.14116
   PubMed Web of Science ®Google Scholar
• Anvari S, Anagnostou K. The nuts and bolts of food immunotherapy: the future of food allergy. Children. 2018;5(4):47. doi:10.3390/children5040047
   Google Scholar
• Eapen AA, Lavery WJ, Siddiqui JS, Lierl MB. Oral immunotherapy for multiple foods in a pediatric allergy clinic setting. Ann Allergy Asthma Immunol. 2019;123(6):573–581.e3. doi:10.1016/j.anai.2019.08.463
   Web of Science ®Google Scholar
• Mori F, Barni S, Liccioli G, Novembre E. Oral immunotherapy (OIT): a personalized medicine. Medicina. 2019;55(10):684. doi:10.3390/medicina55100684
   Web of Science ®Google Scholar
• Wood RA. Oral immunotherapy for food allergy. J Investig Allergol Clin Immunol. 2017;27(3):151–159. doi:10.18176/jiaci.0143
   PubMed Web of Science ®Google Scholar
• Sugiura S, Kitamura K, Makino A, et al. Slow low-dose oral immunotherapy: threshold and immunological change. Allergol Int. 2020;69(4):601–609. doi:10.1016/j.alit.2020.03.008
   Web of Science ®Google Scholar
• Palosuo K, Karisola P, Savinko T, Fyhrquist N, Alenius H, Mäkelä MJ. A randomized, open-label trial of hen’s egg oral immunotherapy: efficacy and humoral immune responses in 50 children. J Allergy Clin Immunol Pract. 2021;9(5):1892–1901.e1. doi:10.1016/j.jaip.2021.01.020
   Web of Science ®Google Scholar
• Romantsik O, Tosca MA, Zappettini S, Calevo MG. Oral and sublingual immunotherapy for egg allergy. Cochrane Database Syst Rev. 2018;4(4):Cd010638.
   Google Scholar
• Inuo C, Tanaka K, Suzuki S, et al. Oral immunotherapy using partially hydrolyzed formula for cow’s milk protein allergy: a randomized, controlled trial. Int Arch Allergy Immunol. 2018;177(3):259–268. doi:10.1159/000490804
   Web of Science ®Google Scholar
• Soller L, Abrams EM, Carr S, et al. First real-world safety analysis of preschool peanut oral immunotherapy. J Allergy Clin Immunol Pract. 2019;7(8):2759–2767.e5. doi:10.1016/j.jaip.2019.04.010
   Web of Science ®Google Scholar
• Jones S, Kim E, Nadeau K, et al. Tolerance development following oral immunotherapy (OIT) in 1–3 year old children with peanut allergy: findings from the Immune Tolerance Network (ITN) IMPACT TRIAL. J Allergy Clin Immunol. 2020;145(2):AB338. doi:10.1016/j.jaci.2019.12.067
   Google Scholar
• Vickery BP, Vereda A, Casale TB, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991–2001.
   Web of Science ®Google Scholar
• Hourihane JOB, Beyer K, Abbas A, et al. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled Phase 3 trial. Lancet. 2020;4(10):728–739.
   Web of Science ®Google Scholar
• Siri D, Kachru R, Griffin N, Vereda A, Smith A, Sher E. Improved tolerability and continued immunomodulation among subjects aged 4–17 years following 12 or 18 months of daily therapeutic AR101 dosing. J Allergy Clin Immunol. 2020;145(2):AB133. doi:10.1016/j.jaci.2019.12.527
   Web of Science ®Google Scholar
• Vickery BP, Vereda A, Nilsson C, et al. Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study. J Allergy Clin Immunol Pract. 2021;9(5):1879–1889.e14. doi:10.1016/j.jaip.2020.12.029
   Web of Science ®Google Scholar
• U.S. Food & Drug Administration. Palforzia. Available from: https://www.fda.gov/vaccines-blood-biologics/allergenics/palforzia. Accessed September 3, 2021.
   Google Scholar
• Bégin P, Winterroth LC, Dominguez T, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014;10(1):1. doi:10.1186/1710-1492-10-1
   PubMed Web of Science ®Google Scholar
• Gasich L, Fergeson J, Ly J. Multi-food oral immunotherapy as safe and effective as single food therapy. J Allergy Clin Immunol. 2020;145(2):AB133. doi:10.1016/j.jaci.2019.12.528
   Web of Science ®Google Scholar
• Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173–181.e8. doi:10.1016/j.jaci.2016.05.027
   PubMed Web of Science ®Google Scholar
• Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803–813. doi:10.1056/NEJMoa1414850
   PubMed Web of Science ®Google Scholar
• Vickery BP, Scurlock AM, Kulis M, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133(2):468–475. doi:10.1016/j.jaci.2013.11.007
   PubMed Web of Science ®Google Scholar
• Nagakura KI, Yanagida N, Sato S, et al. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan. Pediatr Allergy Immunol. 2018;29(5):512–518. doi:10.1111/pai.12898
   Web of Science ®Google Scholar
• Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, Phase 2 study. Lancet. 2019;394(10207):1437–1449. doi:10.1016/S0140-6736(19)31793-3
   PubMed Web of Science ®Google Scholar
• Escudero C, Rodríguez Del Río P, Sánchez-García S, et al. Early sustained unresponsiveness after short-course egg oral immunotherapy: a randomized controlled study in egg-allergic children. Clin Exp Allergy. 2015;45(12):1833–1843. doi:10.1111/cea.12604
   PubMed Web of Science ®Google Scholar
• Nachshon L, Goldberg MR, Katz Y, Levy MB, Elizur A. Long-term outcome of peanut oral immunotherapy-real-life experience. Pediatr Allergy Immunol. 2018;29(5):519–526. doi:10.1111/pai.12914
   Web of Science ®Google Scholar
• Andorf S, Manohar M, Dominguez T, et al. Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab. Allergy Asthma Clin Immunol. 2017;13:51. doi:10.1186/s13223-017-0223-8
   PubMed Web of Science ®Google Scholar
• Yee CSK, Albuhairi S, Noh E, et al. Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab. J Allergy Clin Immunol Pract. 2019;7(2):451–461.e7. doi:10.1016/j.jaip.2018.09.015
   Web of Science ®Google Scholar
• Itazawa T, Adachi Y, Takahashi Y, et al. The severity of reaction after food challenges depends on the indication: a prospective multicenter study. Pediatr Allergy Immunol. 2020;31(2):167–174. doi:10.1111/pai.13140
   Web of Science ®Google Scholar
• Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233–243. doi:10.1056/NEJMoa1200435
   PubMed Web of Science ®Google Scholar
• Grzeskowiak LE, Tao B, Knight E, Cohen-Woods S, Chataway T. Adverse events associated with peanut oral immunotherapy in children - a systematic review and meta-analysis. Sci Rep. 2020;10(1):659. doi:10.1038/s41598-019-56961-3
   Web of Science ®Google Scholar
• Babaie D, Mesdaghi M, Nishino M, Mansouri M, Ebisawa M. Oral and sublingual immunotherapy: potential causes for eosinophilic gastrointestinal disorders? Int Arch Allergy Immunol. 2017;172(2):89–98. doi:10.1159/000457796
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Arias Á, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014;113(6):624–629. doi:10.1016/j.anai.2014.08.004
   PubMed Web of Science ®Google Scholar
• Wright BL, Fernandez-Becker NQ, Kambham N, et al. Baseline gastrointestinal eosinophilia is common in oral immunotherapy subjects with IgE-mediated peanut allergy. Front Immunol. 2018;9:2624. doi:10.3389/fimmu.2018.02624
   Web of Science ®Google Scholar
• Wright BL, Fernandez-Becker NQ, Kambham N, et al. Gastrointestinal eosinophil responses in a longitudinal, randomized trial of peanut oral immunotherapy. Clin Gastroenterol Hepatol. 2021;16(6):1151–1159.e1114. doi:10.1016/j.cgh.2020.05.019
   Web of Science ®Google Scholar
• Sindher S, Long AJ, Purington N, et al. Analysis of a large standardized food challenge data set to determine predictors of positive outcome across multiple allergens. Front Immunol. 2018;9:2689. doi:10.3389/fimmu.2018.02689
   PubMed Web of Science ®Google Scholar
• Yanagida N, Sato S, Asaumi T, Ogura K, Ebisawa M. Risk factors for severe reactions during double-blind placebo-controlled food challenges. Int Arch Allergy Immunol. 2017;172(3):173–182. doi:10.1159/000458724
   Web of Science ®Google Scholar
• Purington N, Chinthrajah RS, Long A, et al. Eliciting dose and safety outcomes from a large dataset of standardized multiple food challenges. Front Immunol. 2018;9:2689. doi:10.3389/fimmu.2018.02057
   Web of Science ®Google Scholar
• Chinthrajah RS, Purington N, Andorf S, et al. Development of a tool predicting severity of allergic reaction during peanut challenge. Ann Allergy Asthma Immunol. 2018;121(1):69–76.e62. doi:10.1016/j.anai.2018.04.020
   PubMed Web of Science ®Google Scholar
• Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3(2):85–94. doi:10.1016/S2468-1253(17)30392-8
   PubMed Web of Science ®Google Scholar
• Davies AM, Allan EG, Keeble AH, et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem. 2017;292(24):9975–9987. doi:10.1074/jbc.M117.776476
   PubMed Web of Science ®Google Scholar
• Lin C, Lee IT, Sampath V, et al. Combining anti-IgE with oral immunotherapy. Pediatr Allergy Immunol. 2017;28(7):619–627. doi:10.1111/pai.12767
   Web of Science ®Google Scholar
• MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873–881 e8. doi:10.1016/j.jaci.2016.08.010
   PubMed Web of Science ®Google Scholar
• Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–1110.e11. doi:10.1016/j.jaci.2015.10.005
   PubMed Web of Science ®Google Scholar
• Sampson HA, Leung DY, Burks AW, et al. A Phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127(5):1309–10.e1. doi:10.1016/j.jaci.2011.01.051
   PubMed Web of Science ®Google Scholar
• Burks AW, Sampson HA, Plaut M, Lack G, Akdis CA. Treatment for food allergy. J Allergy Clin Immunol. 2018;141(1):1–9. doi:10.1016/j.jaci.2017.11.004
   PubMed Web of Science ®Google Scholar
• Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368–1374. doi:10.1016/j.jaci.2013.09.046
   PubMed Web of Science ®Google Scholar
• Bégin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab. Allergy Asthma Clin Immunol. 2014;10(1):7. doi:10.1186/1710-1492-10-7
   PubMed Web of Science ®Google Scholar
• Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127(6):1622–1624. doi:10.1016/j.jaci.2011.04.009
   PubMed Web of Science ®Google Scholar
• Andorf S, Purington N, Kumar D, et al. A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals. EClinicalMedicine. 2019;7:27–38. doi:10.1016/j.eclinm.2018.12.006
   PubMedGoogle Scholar
• Frischmeyer-Guerrerio PA, Masilamani M, Gu W, et al. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2017;140(4):1043–1053.e8. doi:10.1016/j.jaci.2017.03.028
   PubMed Web of Science ®Google Scholar
• Sousa AF, Yang A, Mendes CG, Boufleur K, Torres P, Salles-Cunha P. Safety of oral immunotherapy associated with omalizumab in severe cow’s milk allergy. J Allergy Clin Immunol. 2020;145(2):AB133. doi:10.1016/j.jaci.2019.12.529
   Web of Science ®Google Scholar
• Takahashi M, Soejima K, Taniuchi S, et al. Oral immunotherapy combined with omalizumab for high-risk cow’s milk allergy: a randomized controlled trial. Sci Rep. 2017;7(1):17453. doi:10.1038/s41598-017-16730-6
   PubMed Web of Science ®Google Scholar
• Long A, Borro M, Sampath V, Chinthrajah RS. New developments in non-allergen-specific therapy for the treatment of food allergy. Curr Allergy Asthma Rep. 2020;20(1):3. doi:10.1007/s11882-020-0897-8
   PubMed Web of Science ®Google Scholar
• Sastre J, Dávila I. Dupilumab: a new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol. 2018;28(3):139–150. doi:10.18176/jiaci.0254
   PubMed Web of Science ®Google Scholar
• Macdougall JD, Burks AW, Kim EH. Current insights into immunotherapy approaches for food allergy. Immunotargets Ther. 2021;10:1–8. doi:10.2147/ITT.S266257
   Web of Science ®Google Scholar
• Dupilumab and milk OIT for the treatment of cow’s milk allergy. NLM identifier: NCT04148352. Available from: https://clinicaltrials.gov/ct2/show/NCT04148352. Accessed September 03, 2021.
   Google Scholar
• Study in pediatric subjects with peanut allergy to evaluate efficacy and safety of dupilumab as adjunct to AR101 (peanut oral immunotherapy). NLM identifier: NCT03682770. Available from: https://clinicaltrials.gov/ct2/show/NCT03682770. Accessed September 03, 2021.
   Google Scholar
• Clinical study using biologics to improve multi OIT outcomes. NLM identifier: NCT03679676. Available from: https://clinicaltrials.gov/ct2/show/NCT03679676. Accessed September 03, 2021.
   Google Scholar
• Arasi S, Caminiti L, Crisafulli G, et al. The safety of oral immunotherapy for food allergy during maintenance phase: effect of counselling on adverse reactions. World Allergy Organ J. 2019;12(1):100010. doi:10.1016/j.waojou.2018.11.008
   Web of Science ®Google Scholar
• Chinthrajah RS, Cao S, Dunham T, et al. Oral immunotherapy for peanut allergy: the pro argument. World Allergy Organ J. 2020;13(8):100455. doi:10.1016/j.waojou.2020.100455
   PubMed Web of Science ®Google Scholar
• Bégin P, Chan ES, Kim H, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. Allergy Asthma Clin Immunol. 2020;16(1):20. doi:10.1186/s13223-020-0413-7
   Web of Science ®Google Scholar
• Wasserman RL, Jones DH, Windom HH, et al. Reaching for best practices in food oral immunotherapy: report on the second annual food allergy support team meeting. Ann Allergy Asthma Immunol. 2019;123(2):129–130.e3. doi:10.1016/j.anai.2019.05.002
   Web of Science ®Google Scholar
• Wasserman RL, Jones DH, Windom HH. Oral immunotherapy for food allergy: the FAST perspective. Ann Allergy Asthma Immunol. 2018;121(3):272–275. doi:10.1016/j.anai.2018.06.011
   PubMed Web of Science ®Google Scholar
• Versluis A, Van Os-medendorp H, Kruizinga AG, Blom WM, Houben GF, Knulst AC. Cofactors in allergic reactions to food: physical exercise and alcohol are the most important. Immun Inflamm Dis. 2016;4(4):392–400. doi:10.1002/iid3.120
   PubMed Web of Science ®Google Scholar
• Epstein-Rigbi N, Goldberg MR, Levy MB, Nachshon L, Elizur A. Quality of life of food-allergic patients before, during, and after oral immunotherapy. J Allergy Clin Immunol Pract. 2019;7(2):429–436.e2. doi:10.1016/j.jaip.2018.06.016
   Web of Science ®Google Scholar
• Cao S, Borro M, Alonzi S, Sindher S, Nadeau K, Chinthrajah RS. Improvement in health-related quality of life in food-allergic patients: a meta-analysis. J Allergy Clin Immunol Pract. 2021;9(10):3705–3714.
   Web of Science ®Google Scholar
• Howe LC, Leibowitz KA, Perry MA, et al. Changing patient mindsets about non-life-threatening symptoms during oral immunotherapy: a randomized clinical trial. J Allergy Clin Immunol Pract. 2019;7(5):1550–1559. doi:10.1016/j.jaip.2019.01.022
   Web of Science ®Google Scholar
• Nachshon L, Goldberg MR, Elizur A, Levy MB, Schwartz N, Katz YA. Web site-based reporting system for monitoring home treatment during oral immunotherapy for food allergy. Ann Allergy Asthma Immunol. 2015;114(6):510–515. doi:10.1016/j.anai.2015.04.007
   Web of Science ®Google Scholar